DK3519411T3 - Heterocykliske forbindelser og deres anvendelse inden for forebyggelsen eller behandlingen af bakterieinfektioner - Google Patents

Heterocykliske forbindelser og deres anvendelse inden for forebyggelsen eller behandlingen af bakterieinfektioner Download PDF

Info

Publication number
DK3519411T3
DK3519411T3 DK17783790.3T DK17783790T DK3519411T3 DK 3519411 T3 DK3519411 T3 DK 3519411T3 DK 17783790 T DK17783790 T DK 17783790T DK 3519411 T3 DK3519411 T3 DK 3519411T3
Authority
DK
Denmark
Prior art keywords
prevention
treatment
heterocyclic compounds
bacterial infections
infections
Prior art date
Application number
DK17783790.3T
Other languages
English (en)
Inventor
Julien Barbion
Audrey Caravano
Sophie Chasset
Francis Chevreuil
Fabien Faivre
Rémi Lebel
Nicolas Lecointe
Frédéric Le-Strat
Christophe Simon
Chrystelle Oliveira
Fralliec Géraldine Le
Julie Brias
Laurence Farescour
Sophie Vomscheid
Sébastien Richard
Benoã®T Ledoussal
Original Assignee
Mutabilis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mutabilis filed Critical Mutabilis
Application granted granted Critical
Publication of DK3519411T3 publication Critical patent/DK3519411T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
DK17783790.3T 2016-09-30 2017-09-29 Heterocykliske forbindelser og deres anvendelse inden for forebyggelsen eller behandlingen af bakterieinfektioner DK3519411T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16306261.5A EP3301094A1 (en) 2016-09-30 2016-09-30 Heterocyclic compounds and their use in preventing or treating bacterial infections
PCT/EP2017/074873 WO2018060481A1 (en) 2016-09-30 2017-09-29 Heterocyclic compounds and their use in preventing or treating bacterial infections

Publications (1)

Publication Number Publication Date
DK3519411T3 true DK3519411T3 (da) 2022-07-11

Family

ID=57130331

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17783790.3T DK3519411T3 (da) 2016-09-30 2017-09-29 Heterocykliske forbindelser og deres anvendelse inden for forebyggelsen eller behandlingen af bakterieinfektioner

Country Status (24)

Country Link
US (1) US10722520B2 (da)
EP (3) EP3301094A1 (da)
JP (2) JP7089508B2 (da)
KR (1) KR20190065326A (da)
CN (2) CN109906226B (da)
AR (1) AR109774A1 (da)
AU (1) AU2017335222C1 (da)
BR (1) BR112019006371A2 (da)
CA (1) CA3038221A1 (da)
CL (1) CL2019000857A1 (da)
DK (1) DK3519411T3 (da)
ES (1) ES2927528T3 (da)
HR (1) HRP20220831T1 (da)
HU (1) HUE059938T2 (da)
IL (1) IL265676B (da)
LT (1) LT3519411T (da)
MX (1) MX2019003545A (da)
PL (1) PL3519411T3 (da)
PT (1) PT3519411T (da)
RS (1) RS63473B1 (da)
SI (1) SI3519411T1 (da)
TW (1) TWI801353B (da)
WO (1) WO2018060481A1 (da)
ZA (1) ZA201901963B (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3301094A1 (en) * 2016-09-30 2018-04-04 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
AU2019383311A1 (en) 2018-11-20 2021-06-10 Nflection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
EP4281069A1 (en) * 2021-01-21 2023-11-29 NFlection Therapeutics, Inc. Processes for preparing pyrrolopyridine-aniline compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
ES2361845T3 (es) * 2004-08-18 2011-06-22 Pfizer, Inc. Inhibidores de arn polimerasa dependiente del arn del virus de la hepatitis c y composiciones y tratamientos que utilizan los mismos.
FR2930553B1 (fr) * 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
FR2937034B1 (fr) * 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
US8138189B2 (en) 2009-03-26 2012-03-20 Hoffman-La Roche Inc. Substituted benzene compounds as modulators of the glucocorticoid receptor
TW201319068A (zh) * 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為xia因子抑制劑之環狀p1接合劑
US8791091B2 (en) * 2011-12-02 2014-07-29 Bristol-Myers Squibb Company Aryl dihydropyridinone and piperidinone MGAT2 inhibitors
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
CA2875165C (en) 2012-06-04 2019-11-19 Elkimia Imino compounds as protecting agents against ultraviolet radiations
US9365526B2 (en) 2012-12-31 2016-06-14 Sun Pharmaceutical Industries Limited Process for the preparation of dasatinib and its intermediates
WO2014141132A1 (en) * 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
US20140315876A1 (en) * 2013-03-15 2014-10-23 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
BR112016024235A2 (pt) * 2014-04-18 2017-08-15 Wockhardt Ltd composições farmacêuticas compreendendo agentes antibacterianos
MX2017006383A (es) * 2014-11-17 2017-08-21 Entasis Therapeutics Ltd Terapia de combinacion para el tratamiento de infecciones bacterianas resistentes.
CN105704828A (zh) * 2014-11-25 2016-06-22 中兴通讯股份有限公司 一种资源调度的方法和装置
EP3091018A1 (en) * 2015-05-07 2016-11-09 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
MX2017014080A (es) 2015-05-07 2018-07-06 Mutabilis Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
EP3301094A1 (en) * 2016-09-30 2018-04-04 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections

Also Published As

Publication number Publication date
RU2019109177A (ru) 2020-09-30
EP3519411B1 (en) 2022-06-22
TW201815791A (zh) 2018-05-01
BR112019006371A2 (pt) 2019-06-25
ES2927528T3 (es) 2022-11-08
MX2019003545A (es) 2019-06-17
RU2019109177A3 (da) 2020-11-30
AU2017335222A1 (en) 2019-04-11
TWI801353B (zh) 2023-05-11
IL265676A (en) 2019-05-30
CN109906226B (zh) 2021-11-02
EP3519411A1 (en) 2019-08-07
LT3519411T (lt) 2022-09-12
AU2017335222A2 (en) 2019-05-09
HRP20220831T1 (hr) 2022-09-30
US20190224210A1 (en) 2019-07-25
WO2018060481A1 (en) 2018-04-05
EP4086255A1 (en) 2022-11-09
JP2019530690A (ja) 2019-10-24
PL3519411T3 (pl) 2022-08-22
KR20190065326A (ko) 2019-06-11
JP2022097520A (ja) 2022-06-30
IL265676B (en) 2021-12-01
AU2017335222C1 (en) 2022-01-20
CN109906226A (zh) 2019-06-18
HUE059938T2 (hu) 2023-01-28
CA3038221A1 (en) 2018-04-05
ZA201901963B (en) 2021-01-27
EP3301094A1 (en) 2018-04-04
JP7089508B2 (ja) 2022-06-22
US10722520B2 (en) 2020-07-28
AU2017335222B2 (en) 2021-07-15
AR109774A1 (es) 2019-01-23
CN113929680A (zh) 2022-01-14
CL2019000857A1 (es) 2019-08-09
RS63473B1 (sr) 2022-08-31
SI3519411T1 (sl) 2022-08-31
PT3519411T (pt) 2022-08-25

Similar Documents

Publication Publication Date Title
DK3678668T3 (da) ENPP1-inhibitorer og deres anvendelse til behandling af kræft
DK3307727T3 (da) Heterocykliske inhibitorer af erk1 og erk2 og deres anvendelse i behandlingen af kræft
DK3578547T3 (da) Sulfonylureaer og relaterede forbindelser og brug af samme
DK3285809T3 (da) Inhibitorer af immunkontrolpunktsmodulatorer til anvendelse i behandling af kræft og infektioner.
DK3149019T3 (da) Cholan-derivater til anvendelse ved behandling og/eller forebyggelse af FXR- og TGR5/GPBAR1-formidlede sygdomme
DK3609514T3 (da) Grupper af levende bakterier og deres anvendelse ved behandlingen af mikrobiom-dysbiose
ZA201706348B (en) Heterocyclic compounds and their use in preventing or treating bacterial infections
DK3612517T3 (da) Bicykliske forbindelser og deres anvendelse ved behandling af cancer
DK3220741T3 (da) Sammensætning og kits til hæmning af patogen mikrobiel infektion og fremgangsmåder til anvendelse af samme
DK3641753T3 (da) Bacitracin og/eller daptomycin kombineret med cannabidiol til behandling af bakterieinfektioner
DK3558280T3 (da) Forebyggelse og behandling af migræne
DK3432899T3 (da) Anvendelse af probiotika ved behandling og/eller forebyggelse af psoriasis
DK3576738T3 (da) Gaboxadolmonohydrat i behandling af tinnitus
DK3261642T3 (da) Quinolinderivater til anvendelse ved behandling eller forebyggelse af virusinfektioner
DK3294740T3 (da) Hidtil ukendte sulfonimidoylpurinonforbindelser og derivater til behandling og profylakse af virusinfektion
DK3200748T3 (da) Sammensætninger og fremgangsmåder til behandling og profylakse af infektioner på operationssted
DK3790879T3 (da) Triazolopyrimidinforbindelser og deres anvendelse til behandling af kræft
DK3268374T3 (da) Kv1.3-inhibitorer og deres medicinske anvendelse
DK3722291T3 (da) Indolinonforbindelser og deres anvendelse i behandlingen af fibrotiske sygdomme
DK3752506T3 (da) Pyrimidinderivater til forebyggelse og behandling af bakterielle infektioner
DK3102218T3 (da) Behandling af topiske og systemiske bakterieinfektioner
DK3522873T3 (da) Sammensætninger og fremgangsmåder til behandlingen af xerostomi
DK3519411T3 (da) Heterocykliske forbindelser og deres anvendelse inden for forebyggelsen eller behandlingen af bakterieinfektioner
DK3476397T3 (da) Nye sammensætninger og deres anvendelse til behandling af bakterielle infektioner
DK3444010T3 (da) Pklr-inhibering i behandlingen af nafld og hcc